Microbiological and Inflammatory Effects of Murine Recombinant Interleukin-10 in Two Models of Polymicrobial Peritonitis in Rats

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1999 Mar 20

PMID 10084989

Citations 4

Authors

P Montravers

L Maulin

J Mohler

C Carbon

Affiliations

Soon will be listed here.

Abstract

A protective effect of interleukin-10 (IL-10) against the development of lethal shock has been demonstrated in various animal models. In contrast, the immunosuppressant properties of this mediator have been minimally evaluated in low-mortality models of infections. The clinical, microbiological, and inflammatory effects of murine recombinant IL-10 (mrIL-10) therapy were evaluated in two models of peritonitis in rats, which differed in the degree of severity of peritoneal inflammation 3 days after inoculation of Escherichia coli and Bacteroides fragilis with or without Enterococcus faecalis. The severity of the disease remained unchanged compared to that in control animals. A dose-related decrease in the peritoneal phagocyte count was observed in the treated groups compared to the counts in control animals. The subsequent experiments were performed exclusively in the mixed gram-positive-gram negative model, which exhibits an intense and prolonged inflammatory response with similar criteria. The early effects of mrIL-10 (evaluated 6 h after inoculation), repeated injections of mrIL-10 (four doses injected from 0 to 9 h after bacterial challenge), and pretreatment (two doses injected 6 and 3 h before inoculation) were evaluated. The clinical and microbiological parameters remained unchanged in the treated animals. Decreases in the peritoneal phagocyte count and the peritoneal concentration of tumor necrosis factor were observed following repeated injections of mrIL-10. In summary, our data suggest that mrIL-10 does not worsen the manifestations of sepsis. However, these results need to be confirmed in clinical practice.

Citing Articles

Local IL-10 delivery modulates the immune response and enhances repair of volumetric muscle loss muscle injury.

Huynh T, Reed C, Blackwell Z, Phelps P, Herrera L, Almodovar J Sci Rep. 2023; 13(1):1983.

PMID: 36737628 PMC: 9898301. DOI: 10.1038/s41598-023-27981-x.

Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model.

Buyne O, Bleichrodt R, Goor H, Verweij P, Hendriks T Int J Colorectal Dis. 2006; 22(7):819-25.

PMID: 17089129 DOI: 10.1007/s00384-006-0222-6.

A peritonitis model with low mortality and persisting intra-abdominal abscesses.

Buyne O, Bleichrodt R, Verweij P, Groenewoud H, Goor H, Hendriks T Int J Exp Pathol. 2006; 87(5):361-8.

PMID: 16965563 PMC: 2517383. DOI: 10.1111/j.1365-2613.2006.00488.x.

Developing animal models for polymicrobial diseases.

Bakaletz L Nat Rev Microbiol. 2004; 2(7):552-68.

PMID: 15197391 PMC: 7097426. DOI: 10.1038/nrmicro928.

References

van der Poll T, Marchant A, Buurman W, Berman L, Keogh C, Lazarus D . Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol. 1995; 155(11):5397-401. View

van der Poll T, Marchant A, Keogh C, Goldman M, Lowry S . Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis. 1996; 174(5):994-1000. DOI: 10.1093/infdis/174.5.994. View

Mulligan M, Jones M, Vaporciyan A, HOWARD M, Ward P . Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol. 1993; 151(10):5666-74. View

Cox G . IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol. 1996; 271(4 Pt 1):L566-71. DOI: 10.1152/ajplung.1996.271.4.L566. View

van der Poll T, Jansen P, Montegut W, Braxton C, Calvano S, Stackpole S . Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol. 1997; 158(4):1971-5. View

Mosmann T . Properties and functions of interleukin-10. Adv Immunol. 1994; 56:1-26. View

Berg D, Kuhn R, Rajewsky K, Muller W, Menon S, Davidson N . Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995; 96(5):2339-47. PMC: 185885. DOI: 10.1172/JCI118290. View

Greenberger M, Strieter R, Kunkel S, Danforth J, Goodman R, Standiford T . Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol. 1995; 155(2):722-9. View

Cross A, Opal S, Sadoff J, Gemski P . Choice of bacteria in animal models of sepsis. Infect Immun. 1993; 61(7):2741-7. PMC: 280916. DOI: 10.1128/iai.61.7.2741-2747.1993. View

10.

Shoemaker W, Appel P, Kram H, BISHOP M, Abraham E . Sequence of physiologic patterns in surgical septic shock. Crit Care Med. 1993; 21(12):1876-89. DOI: 10.1097/00003246-199312000-00015. View

11.

Moore K, Vieira P, Fiorentino D, Trounstine M, Khan T, Mosmann T . Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990; 248(4960):1230-4. DOI: 10.1126/science.2161559. View

12.

Kato T, Murata A, Ishida H, Toda H, Tanaka N, Hayashida H . Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother. 1995; 39(6):1336-40. PMC: 162737. DOI: 10.1128/AAC.39.6.1336. View

13.

Pajkrt D, Camoglio L, De Bruin K, Cutler D, Affrime M, Rikken G . Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol. 1997; 158(8):3971-7. View

14.

Cenci E, Romani L, Mencacci A, Spaccapelo R, Schiaffella E, Puccetti P . Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol. 1993; 23(5):1034-8. DOI: 10.1002/eji.1830230508. View

15.

Weinstein W, Onderdonk A, Bartlett J, Gorbach S . Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun. 1974; 10(6):1250-5. PMC: 423095. DOI: 10.1128/iai.10.6.1250-1255.1974. View

16.

Paris M, Hickey S, Trujillo M, Ahmed A, Olsen K, McCracken Jr G . The effect of interleukin-10 on meningeal inflammation in experimental bacterial meningitis. J Infect Dis. 1997; 176(5):1239-46. DOI: 10.1086/514118. View

17.

van Deventer S, Elson C, Fedorak R . Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997; 113(2):383-9. DOI: 10.1053/gast.1997.v113.pm9247454. View

18.

Montravers P, Mohler J, Saint Julien L, Carbon C . Evidence of the proinflammatory role of Enterococcus faecalis in polymicrobial peritonitis in rats. Infect Immun. 1997; 65(1):144-9. PMC: 174568. DOI: 10.1128/iai.65.1.144-149.1997. View

19.

Opal S, Fisher Jr C, Dhainaut J, Vincent J, Brase R, Lowry S . Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997; 25(7):1115-24. DOI: 10.1097/00003246-199707000-00010. View

20.

Montravers P, Andremont A, Massias L, Carbon C . Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis. 1994; 169(4):821-30. DOI: 10.1093/infdis/169.4.821. View